Two samples of Dasatinib the same condition were combined into one to obtain enough RNA for analysis. A previously described protocol was used to extract the total RNA from the cut pieces.31 To remove genomic DNA, the RNA samples were incubated with RNase-free DNase I (New England BioLabs, M0303S) in conjunction with the use of an RNase inhibitor (Life Technologies, N808�C0119). The cDNA was prepared by annealing the RNA with random hexamer and oligo dT primers and allowing the first strand synthesis to be performed with MuLV reverse transcriptase (Life Technologies, N808�C0234). No reverse transcriptase was used in the negative controls. An Applied Biosystems 7300 Real-Time PCR system was used to carry out real-time PCR analysis.

ABI TaqMan gene expression assays for rat collagen 1�� (Rn00801649-gl), elastin (Rn01499782-m1), lysyl oxidase (Rn00566984-m1), ��-smooth muscle actin (Mn01546133-m1), Vegf (Rn01511605-m1), syndecan-4 (Rn00561900-m1), ��1 integrin (Mn01253227-m1) and ��3 integrin (Rn00596601-m1) were used as target probes. Eukaryotic 18 S rRNA (4308329) was used as an endogenous control. Standard cycling parameters of 50��C for 10 min, 95��C for 2 min, and 40 cycles of 95��C for 15 sec and 60��C for 1 min were completed. Data were analyzed with the ����CT method with 18 S rRNA as the endogenous control. Statistical analysis Data are presented as mean �� standard deviation for each group. Data were analyzed using one-way Anova and differences between groups were considered statistically different for p < 0.05. Disclosure of Potential Conflicts of Interest No potential conflicts of interest were disclosed.

Acknowledgments This work was supported by NIH grants HL-098976 and HL-088572. Footnotes Previously published online: www.landesbioscience.com/journals/biomatter/article/24650
Researchers have identified and isolated mesenchymal stem cells from numerous different tissues, including (but not limited to) bone marrow, adipose tissue, skeletal muscle, synovium and dental pulp.1-5 Although many of these cell types have exhibited promising results for tissue engineering and regeneration, there are still many limitations in harvesting tissues from some of these sources, such as donor site morbidity6,7 and the necessity for in vitro expansion and/or purification prior to re-implantation.

8 More recently, it was found that vascular endothelial cells transform into mesenchymal stem cells through the process of EndMT. It has been shown that these cells exhibit multipotency by their ability to differentiate into osteoblasts, chondrocytes, adipocytes, smooth muscle cells or fibroblasts in vitro and in vivo.9-11 These cells may have the ability to overcome some of the limitations of mesenchymal stem cells derived from other tissues. Here we provide a brief overview Carfilzomib of EndMT in generating endothelial-derived stem cells and their potential use for regenerative medicine.